Synthetic antibodies as therapeutics

Bibliography

• REICHERT JM, ROSENSWEIG CJ, FADEN LB, DEWITZ MC: Monoclonal antibody successes in the clinic. Nat. Biotechnol. (2005) 23(9):1073-1078.
   PubMed Web of Science ®Google Scholar
• TABRIZI MA, TSENG CM, ROSKOS LK: Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discov. Today (2006) 11(1-2):81-88.
   PubMed Web of Science ®Google Scholar
• CARTER PJ: Potent antibody therapeutics by design. Nat. Rev. Immunol. (2006) 6(5):343-357.
   PubMed Web of Science ®Google Scholar
• PRESTA LG: Selection, design, and engineering of therapeutic antibodies. J. Allergy Clin. Immunol. (2005) 116(4):731-736; quiz 737.
   PubMed Web of Science ®Google Scholar
• KOHLER G, MILSTEIN C: Continuous cultures of fused cells secreting antibody of predefined specificity. Nature (1975) 256(5517):495-497.
   PubMed Web of Science ®Google Scholar
• MORRISON SL, JOHNSON MJ, HERZENBERG LA, OI VT: Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc. Natl. Acad. Sci. USA (1984) 81(21):6851-6855.
   PubMed Web of Science ®Google Scholar
• BOULIANNE GL, HOZUMI N, SHULMAN MJ: Production of functional chimaeric mouse/human antibody. Nature (1984) 312(5995):643-646.
   PubMed Web of Science ®Google Scholar
• JONES PT, DEAR PH, FOOTE J, NEUBERGER MS, WINTER G: Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature (1986) 321(6069):522-525.
   PubMed Web of Science ®Google Scholar
• BACA M, PRESTA LG, O’CONNOR SJ, WELLS JA: Antibody humanization using monovalent phage display. J. Biol. Chem. (1997) 272:10678-10684.
   PubMed Web of Science ®Google Scholar
• LONBERG N: Human antibodies from transgenic animals. Nat. Biotechnol. (2005) 23(9):1117-1125.
   PubMed Web of Science ®Google Scholar
• MCCAFFERTY J, GRIFFITHS AD, WINTER G, CHISWELL DJ: Phage antibodies: filamentous phage displaying antibody variable domains. Nature (1990) 348:552-554.
   PubMed Web of Science ®Google Scholar
• HUSE WD, SASTRY L, IVERSON SA et al.: Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambda. Science (1989) 246(4935):1275-1281.
   PubMed Web of Science ®Google Scholar
• HOOGENBOOM HR: Selecting and screening recombinant antibody libraries. Nat. Biotechnol. (2005) 23(9):1105-1116.
   PubMed Web of Science ®Google Scholar
• SMITH GP, SCOTT JK: Libraries of peptides and proteins displayed on filamentous phage. Methods Enzymol. (1993) 217:228-257.
   PubMed Web of Science ®Google Scholar
• HANES J, PLUCKTHUN A: In vitro selection and evolution of functional proteins by using ribosome display. Proc. Natl. Acad. Sci. USA (1997) 94:4937-4942.
   PubMed Web of Science ®Google Scholar
• KIEKE MC, CHO BK, BODER ET, KRANZ DM, WITTRUP KD: Isolation of anti-T cell receptor scFv mutants by yeast display. Protein Eng. (1997) 10:1303-1310.
   PubMedGoogle Scholar
• GEORGIOU G, STATHOPOULOS C, DAUGHERTY PS et al.: Display of heterologous proteins on the surface of microorganism from the screening of combinatorial libraries to live recombinant vaccines. Nat. Biotechnol. (1997) 15:29-34.
   PubMed Web of Science ®Google Scholar
• DE HAARD HJ, VAN NEER N, REURS A et al.: A large non-immunized human Fab fragment phage library that permits rapid isolation and kinetic analysis of high affinity antibodies. J. Biol. Chem. (1999) 274(26):18218-18230.
   PubMed Web of Science ®Google Scholar
• VAUGHAN TJ, WILLIAMS AJ, PRITCHARD K et al.: Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library. Nat. Biotechnol. (1996) 14:309-314.
   PubMed Web of Science ®Google Scholar
• SHEETS MD, AMERSDORFER P, FINNERN R et al.: Efficient construction of a large nonimmune phage antibody library: the production of high-affinity human single-chain antibodies to protein antigens. Proc. Natl. Acad. Sci. USA (1998) 95:6157-6162.
   PubMed Web of Science ®Google Scholar
• JIRHOLT P, OHLIN M, BORREBAECK CA, SODERLIND E: Exploiting sequence space: shuffling in vivo formed complementarity determining regions into a master framework. Gene (1998) 215(2):471-476.
   PubMed Web of Science ®Google Scholar
• CLACKSON T, HOOGENBROOM HR, GRIFFITHS AD, WINTER G: Making antibody fragments using phage display libraries. Nature (1991) 352:624-628.
   PubMed Web of Science ®Google Scholar
• BRADBURY AR, MARKS JD: Antibodies from phage antibody libraries. J. Immunol. Methods (2004) 290:29-49.
   PubMed Web of Science ®Google Scholar
• DOBSON CL, MINTER RR, HART-SHORROCK CP: Naive antibody libraries from natural repertoires. In: Phage Display in Biotechnology and Drug Discovery. Sidhu SS (Ed.), CRC Press, Taylor & Francis Group, UK (2006):659-708.
   Google Scholar
• AL-LAZIKANI B, LESK AM, CHOTHIA C: Standard conformations for the canonical structures of immunoglobulins. J. Mol. Biol. (1997) 273:927-948.
   PubMed Web of Science ®Google Scholar
• JOHNSON G, WU TT: Kabat database and its applications: 30 years after the first variability plot. Nucleic Acids Res. (2000) 28:214-218.
   PubMed Web of Science ®Google Scholar
• CHOTHIA C, LESK AM, GHERARDI E et al.: Structural repertoire of the human VH segments. J. Mol. Biol. (1992) 227(3):799-817.
   PubMed Web of Science ®Google Scholar
• SBLATTERO D, BRADBURY A: Exploiting recombination in single bacteria to make large phage antibody libraries. Nat. Biotechnol. (2000) 18:75-80.
   PubMed Web of Science ®Google Scholar
• JUNG S, HONEGGER A, PLUCKTHUN A: Selection for improved protein stability by phage display. J. Mol. Biol. (1999) 294(1):163-180.
   PubMed Web of Science ®Google Scholar
• EWERT S, HUBER T, HONEGGER A, PLUCKTHUN A: Biophysical properties of human antibody variable domains. J. Mol. Biol. (2003) 325(3):531-553.
   PubMed Web of Science ®Google Scholar
• JESPERS LS, ROBERTS A, MAHLER SM, WINTER G, HOOGENBOOM HR: Guiding the selection of human antibodies from phage display repertoires to a single epitope of an antigen. Biotechnology (NY) (1994) 12(9):899-903.
   PubMedGoogle Scholar
• FELLOUSE F, SIDHU SS: Synthetic antibody libraries. In: Phage Display in Biotechnology and Drug Discovery. Sidhu SS (Ed.), CRC Press, Taylor and Francis Group, UK (2006):709-740.
   Google Scholar
• BARBAS CF, BAIN JD, HOEKSTRA DM, LERNER RA: Semisynthetic combinatorial Ab libraries: a chemical solution to the diversity problem. Proc. Natl. Acad. Sci. USA (1992) 89:4457-4461.
   PubMed Web of Science ®Google Scholar
• XU JL, DAVIS MM: Diversity in the CDR3 region of V(H) is sufficient for most antibody specificities. Immunity (2000) 13(1):37-45.
   PubMed Web of Science ®Google Scholar
• WILSON IA, STANFIELD RL: Antibody-antigen interactions: new structures and new conformational changes. Curr. Opin. Struct. Biol. (1994) 4:857-867.
   PubMed Web of Science ®Google Scholar
• PADLAN EA: Anatomy of the antibody molecule. Mol. Immunol. (1994) 31:169-217.
   PubMed Web of Science ®Google Scholar
• CHOTHIA C, LESK AM, TRAMONTANO A et al.: Conformations of immunoglobulin hypervariable regions. Nature (1989) 342:877-883.
   PubMed Web of Science ®Google Scholar
• BARBAS CF 3RD, AMBERG W, SIMONCSITS A, JONES TM, LERNER RA: Selection of human anti-hapten antibodies from semisynthetic libraries. Gene (1993) 137(1):57-62.
   PubMed Web of Science ®Google Scholar
• MACCALLUM RM, MARTIN AC, THORNTON JM: Antibody-Antigen interactions: contact analysis and binding site topology. J. Mol. Biol. (1996) 262:732-745.
   PubMed Web of Science ®Google Scholar
• GARRARD LJ, HENNER DJ: Selection of an anti-IGF-1 Fab from a Fab phage library created by mutagenesis of multiple CDR loops. Gene (1993) 128:103-109.
   PubMed Web of Science ®Google Scholar
• KABAT EA, WU TT, PERRY HM, GOTTESMAN KS, FOELLER C: Sequences of Proteins of Immunological Interest. Kabat EA, Wu TT, Perry HM, Gottesman KS, Foeller C (Eds), NIH, US Department of Health and Human Services, Washington, DC, USA (1991).
   Google Scholar
• HOOGENBOOM HR, WINTER G: By-passing immunisation. Human antibodies from synthetic repertoires of germline VH gene segments rearranged in vitro. J. Mol. Biol. (1992) 227(2):381-388.
   PubMed Web of Science ®Google Scholar
• NISSIM A, HOOGENBOOM HR, TOMLINSON IM et al.: Antibody fragments from a ‘single pot’ phage display library as immunochemical reagents. EMBO J. (1994) 13(3):692-698.
   PubMed Web of Science ®Google Scholar
• WATERHOUSE P, GRIFFITHS AD, JOHNSON KS, WINTER G: Combinatorial infection and in vivo recombination: a strategy for making large phage antibody repertoires. Nucleic Acids Res. (1993) 21(9):2265-2266.
   PubMed Web of Science ®Google Scholar
• GRIFFITHS AD, WILLIAMS SC, HARTLEY O et al.: Isolation of high affinity human antibodies directly from large synthetic repertoires. EMBO J. (1994) 13:3245-3260.
   PubMed Web of Science ®Google Scholar
• DE KRUIF J, BOEL E, LOGTENBERG T: Selection and application of human single chain Fv antibody fragments from a semi-synthetic phage antibody display library with designed CDR3 regions. J. Mol. Biol. (1995) 248:97-105.
   PubMed Web of Science ®Google Scholar
• PINI A, VITI F, SANTUCCI A et al.: Design and use of a phage display library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel. J. Biol. Chem. (1998) 273(34):21769-21776.
   PubMed Web of Science ®Google Scholar
• KIRKHAM PM, MORTARI F, NEWTON JA, SCHROEDER HW JR: Immunoglobulin VH clan and family identity predicts variable domain structure and may influence antigen binding. EMBO J. (1992) 11(2):603-609.
   PubMed Web of Science ®Google Scholar
• TOMLINSON IM, WALTER G, MARKS JD, LLEWELYN MB, WINTER G: The repertoire of human germline VH sequences reveals about fifty groups of VH segments with different hypervariable loops. J. Mol. Biol. (1992) 227(3):776-798.
   PubMed Web of Science ®Google Scholar
• DESIDERIO A, FRANCONI R, LOPEZ M et al.: A semi-synthetic repertoire of intrinsically stable antibody fragments derived from a single-framework scaffold. J. Mol. Biol. (2001) 310:603-615.
   PubMed Web of Science ®Google Scholar
• SILACCI M, BRACK S, SCHIRRU G et al.: Design, construction, and characterization of a large synthetic human antibody phage display library. Proteomics (2005) 5(9):2340-2350.
   PubMed Web of Science ®Google Scholar
• KNAPPIK A, GE L, HONEGGER A et al.: Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides. J. Mol. Biol. (2000) 296:57-86.
   PubMed Web of Science ®Google Scholar
• KRETZSCHMAR T, VON RUDEN T: Antibody discovery: phage display. Curr. Opin. Biotechnol. (2002) 13:598-602.
   PubMed Web of Science ®Google Scholar
• VIRNEKAS B, GE L, PLUCKTHUN A et al.: Trinucleotide phosphoramidites: ideal reagents for the synthesis of mixed oligonucleotides for random mutagenesis. Nucleic Acids Res. (1994) 22(25):5600-5607.
   PubMed Web of Science ®Google Scholar
• BRAUNAGEL M, LITTLE M: Construction of a semisynthetic antibody library using trinucleotide oligos. Nucleic Acids Res. (1997) 25(22):4690-4691.
   PubMed Web of Science ®Google Scholar
• RAUCHENBERGER R, BORGES E, THOMASSEN-WOLF E et al.: Human combinatorial Fab library yielding specific and functional antibodies against the human fibroblast growth factor receptor 3. J. Biol. Chem. (2003) 278:38194-38205.
   PubMed Web of Science ®Google Scholar
• BOEHNCKE WH, OCHSENDORF FR, NOLL S et al.: Efficacy of the fully human monoclonal antibody MOR102 (5) against intercellular adhesion molecule 1 in the psoriasis-severe combined immunodeficient mouse model. Br. J. Dermatol. (2005) 153:758-766.
   PubMed Web of Science ®Google Scholar
• SIDHU SS, LI B, FELLOUSE F, EIGENBROT C, FUH G: Phage-displayed antibody libraries of synthetic heavy chain complementarity determining regions. J. Mol. Biol. (2004) 338:299-310.
   PubMed Web of Science ®Google Scholar
• LEE CV, LIANG WC, DENNIS MS et al.: High-affinity human antibodies from phage-displayed synthetic Fab libraries with a single framework scaffold. J. Mol. Biol. (2004) 340(5):1073-1093.
   PubMed Web of Science ®Google Scholar
• CARTER P, PRESTA L, GORMAN CM et al.: Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc. Natl. Acad. Sci. USA (1992) 89:4285-4289.
   PubMed Web of Science ®Google Scholar
• CARTER P, KELLEY RF, RODRIGUES ML et al.: High level Escherichia coli expression and production of a bivalent humanized antibody fragment. Bio/Tech (1992) 10:163-167.
   PubMed Web of Science ®Google Scholar
• EIGENBROT C, RANDAL M, PRESTA L, CARTER P, KOSSIAKOFF AA: X-ray structures of the antigen-binding domains from three variants of humanized anti-p185HER2 antibody 4D5 and comparison with molecular modeling. J. Mol. Biol. (1993) 229(4):969-995.
   PubMed Web of Science ®Google Scholar
• LEE CV, SIDHU SS, FUH G: Bivalent antibody phage display mimics natural immunoglobulin. J. Immunol. Methods (2004) 284:119-132.
   PubMed Web of Science ®Google Scholar
• LEE CV, HYMOWITZ SG, WALLWEBER HJ et al.: Synthetic anti-BR3 antibodies that mimic BAFF binding and target both human and murine B cells. Blood (2006) 108:3103-3111
   PubMed Web of Science ®Google Scholar
• FELLOUSE FA, WIESMANN C, SIDHU SS: Synthetic antibodies from a four-amino-acid code: a dominant role for tyrosine in antigen recognition. Proc. Natl. Acad. Sci. USA (2004) 101(34):12467-12472.
   PubMed Web of Science ®Google Scholar
• FELLOUSE FA, LI B, COMPAAN DM et al.: Molecular recognition by a binary code. J. Mol. Biol. (2005) 348(5):1153-1162.
   PubMed Web of Science ®Google Scholar
• FELLOUSE FA, BARTHELEMY PA, KELLEY RF, SIDHU SS: Tyrosine plays a dominant functional role in the paratope of a synthetic antibody derived from a four amino acid code. J. Mol. Biol. (2006) 357(1):100-114.
   PubMed Web of Science ®Google Scholar
• PADLAN EA: On the nature of antibody combining sites: unusual structural features that may confer on these sites an enhanced capacity for binding ligands. Proteins (1990) 7:112-124.
   PubMed Web of Science ®Google Scholar
• MIAN IS, BRADBURY A, OLSON AJ: Structure, function and properties of antibody binding sites. J. Mol. Biol. (1991) 217:133-151.
   PubMed Web of Science ®Google Scholar
• HOET RM, COHEN EH, KENT RB et al.: Generation of high-affinity human antibodies by combining donor-derived and synthetic complementarity-determining-region diversity. Nat. Biotechnol. (2005) 23(3):344-348.
   PubMed Web of Science ®Google Scholar
• BARBAS CF 3RD, LANGUINO LR, SMITH JW: High-affinity self-reactive human antibodies by design and selection: targeting the integrin ligand binding site. Proc. Natl. Acad. Sci. USA (1993) 90(21):10003-10007.
   PubMed Web of Science ®Google Scholar
• KIRKHAM PM, NERI D, WINTER G: Towards the design of an antibody that recognises a given protein epitope. J. Mol. Biol. (1999) 285(3):909-915.
   PubMed Web of Science ®Google Scholar
• ALMAGRO JC: Identification of differences in the specificity-determining residues of antibodies that recognize antigens of different size: implications for the rational design of antibody repertoires. J. Mol. Recognit. (2004) 17(2):132-143.
   PubMed Web of Science ®Google Scholar
• COLLIS AV, BROUWER AP, MARTIN AC: Analysis of the antigen combining site: correlations between length and sequence composition of the hypervariable loops and the nature of the antigen. J. Mol. Biol. (2003) 325:337-354.
   PubMed Web of Science ®Google Scholar
• PERSSON H, LANTTO J, OHLIN M: A focused antibody library for improved hapten recognition. J. Mol. Biol. (2006) 357(2):607-620.
   PubMed Web of Science ®Google Scholar
• FUH G, WU P, LIANG WC et al.: Structure-function studies of two synthetic anti-vascular endothelial growth factor Fabs and comparison with the Avastin Fab. J. Biol. Chem. (2006) 281(10):6625-6631.
   PubMed Web of Science ®Google Scholar
• LI B, RUSSELL SJ, COMPAAN DM et al.: Activation of the proapoptotic death receptor DR5 by oligomeric peptide and antibody agonists. J. Mol. Biol. (2006) 361(3):522-536.
   PubMed Web of Science ®Google Scholar
• SCHWABE RF, HESS S, JOHNSON JP, ENGELMANN H: Modulation of soluble CD40 ligand bioactivity with anti-CD40 antibodies. Hybridoma (1997) 16:217-226.
   PubMed Web of Science ®Google Scholar
• ICHIKAWA K, LIU W, ZHAO L et al.: Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatic cytotoxicity. Nat. Med. (2001) 7:954-960.
   PubMed Web of Science ®Google Scholar
• SUN Y, CHEN HM, SUBUDHI SK et al.: Costimulatory molecule-targeted antibody therapy of a spontaneous autoimmune disease. Nat. Med. (2002) 8:1256-1258.
   Google Scholar
• GONZALEZ-CUADRADO S, LOPEZ-ARMADA MJ, GOMEZ-GUERRERO C et al.: Anti-Fas antibodies induce cytolysis and apoptosis in cultured human mesangial cells. Kidney Int. (1996) 49:1064-1070.
   PubMed Web of Science ®Google Scholar
• MENEGAZZI R, CRAMER R, PATRIARCA P, SCHEURICH P, DRI P: Evidence that tumor necrosis factor alpha (TNF) induced activation of neutrophil respiratory burst on biologic surface is mediated by the p55 TNF receptor. Blood (1994) 84:287-293.
   PubMed Web of Science ®Google Scholar
• KIM HM, YU KS, LEE ME et al.: Crystal structure of the BAFF-BAFF-R complex and its implications for receptor activation. Nat. Struct. Biol. (2003) 10(5):342-348.
   Google Scholar
• DELGADO C, PEDLEY RB, HERRAEZ A et al.: Enhanced tumour specificity of an anti-carcinoembrionic antigen Fab’ fragment by poly(ethylene glycol) (PEG) modification. Br. J. Cancer (1996) 73(2):175-182.
   PubMed Web of Science ®Google Scholar
• KNIGHT DM, JORDAN RE, KRUSZYNSKI M et al.: Pharmacodynamic enhancement of the anti-platelet antibody fab abciximab by site-specific pegylation. Platelets (2004) 15(7):409-418.
   PubMed Web of Science ®Google Scholar
• SHAUNAK S, GODWIN A, CHOI JW et al.: Site-specific PEGylation of native disulfide bonds in therapeutic proteins. Nat. Chem. Biol. (2006) 2(6):312-313.
   Google Scholar
• DENNIS MS, ZHANG M, MENG YG et al.: Albumin binding as a general strategy for improving the pharmacokinetics of proteins. J. Biol. Chem. (2002) 277:35025-35043.
   PubMed Web of Science ®Google Scholar
• HELDIN CH: Dimerization of cell surface receptors in signal transduction. Cell (1995) 80:213-223.
   PubMed Web of Science ®Google Scholar
• WELLS JA, CUNNINGHAM BC, FUH G et al.: The molecular basis for growth hormone-receptor interactions. Recent Prog. Horm. Res. (1993) 48:253-275.
   PubMedGoogle Scholar
• FUH G, CUNNINGHAM BC, FUKUNAGA R et al.: Rational design of potent antagonists to the human growth hormone receptor. Science (1992) 256(5064):1677-1680.
   PubMed Web of Science ®Google Scholar
• WAN Y, ZHENG YZ, HARRIS JM, BROWN R, WATERS MJ: Epitope map for a growth hormone receptor agonist monoclonal antibody, MAb 263. Mol. Endocrinol. (2003) 17(11):2240-2250.
   PubMed Web of Science ®Google Scholar
• WALPORT MJ: Complement. Second of two parts. N. Engl. J. Med. (2001) 344(15):1140-1144.
   PubMed Web of Science ®Google Scholar
• WALPORT MJ: Complement. First of two parts. N. Engl. J. Med. (2001) 344(14):1058-1066.
   PubMed Web of Science ®Google Scholar
• RAVETCH JV, BOLLAND S: IgG Fc receptors. Annu. Rev. Immunol. (2001) 19:275-290.
   PubMed Web of Science ®Google Scholar
• WEINER LM, CARTER P: Tunable antibodies. Nat. Biotechnol. (2005) 23(5):556-557.
   PubMed Web of Science ®Google Scholar
• FERRARA C, BRUNKER P, SUTER T et al.: Modulation of therapeutic antibody effector functions by glycosylation engineering: influence of Golgi enzyme localization domain and co-expression of heterologous beta1, 4-N-acetylglucosaminyltransferase III and Golgi alpha-mannosidase II. Biotechnol. Bioeng. (2006) 93(5):851-861.
   PubMed Web of Science ®Google Scholar
• KANEKO Y, NIMMERJAHN F, RAVETCH JV: Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science (2006) 313(5787):670-673.
   PubMed Web of Science ®Google Scholar
• SHINKAWA T, NAKAMURA K, YAMANE N et al.: The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J. Biol. Chem. (2003) 278(5):3466-3473.
   PubMed Web of Science ®Google Scholar
• SHIELDS RL, LAI J, KECK R et al.: Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J. Biol. Chem. (2002) 277(30):26733-26740.
   PubMed Web of Science ®Google Scholar
• SHIELDS RL, NAMENUK AK, HONG K et al.: High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J. Biol. Chem. (2001) 276(9):6591-6604.
   PubMed Web of Science ®Google Scholar
• CARTRON G, DACHEUX L, SALLES G et al.: Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood (2002) 99(3):754-758.
   PubMed Web of Science ®Google Scholar
• WENG WK, LEVY R: Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J. Clin. Oncol. (2003) 21(21):3940-3947.
   PubMed Web of Science ®Google Scholar
• ANOLIK JH, CAMPBELL D, FELGAR RE et al.: The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum. (2003) 48(2):455-459.
   PubMed Web of Science ®Google Scholar
• TEELING JL, FRENCH RR, CRAGG MS et al.: Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood (2004) 104(6):1793-1800.
   PubMed Web of Science ®Google Scholar
• TEELING JL, MACKUS WJ, WIEGMAN LJ et al.: The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J. Immunol. (2006) 177(1):362-371.
   PubMed Web of Science ®Google Scholar
• DOEKES G, VAN ES LA, DAHA MR: Binding and activation of the first complement component by soluble immune complexes: effect of complex size and composition. Scand. J. Immunol. (1984) 19(2):99-110.
   Google Scholar
• NANGAKU M, COUSER WG: Mechanisms of immune-deposit formation and the mediation of immune renal injury. Clin. Exp. Nephrol. (2005) 9(3):183-191.
   PubMedGoogle Scholar
• NOWAKOWSKI A, WANG C, POWERS DB et al.: Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody. Proc. Natl. Acad. Sci. USA (2002) 99(17):11346-11350.
   PubMed Web of Science ®Google Scholar
• POPKOV M, JENDREYKO N, GONZALEZ-SAPIENZA G et al.: Human/mouse cross-reactive anti-VEGF receptor 2 recombinant antibodies selected from an immune b9 allotype rabbit antibody library. J. Immunol. Methods (2004) 288(1-2):149-164.
   PubMed Web of Science ®Google Scholar
• MULLER YA, CHEN Y, CHRISTINGER HW et al.: VEGF and the FAB fragment of a humanized neutralizing antibody: crystal structure of the complex at 2.4 A resolution and mutational analysis of the interface. Structure (1998) 6:1153-1167.
   PubMed Web of Science ®Google Scholar
• DONG J, GRUNSTEIN J, TEJADA M et al.: VEGF-null cells require PDGFR alpha signaling-mediated stromal fibroblast recruitment for tumorigenesis. EMBO J. (2004) 23(14):2800-2810.
   PubMed Web of Science ®Google Scholar
• MALIK AK, BALDWIN ME, PEALE F et al.: Redundant roles of VEGF-B and PlGF during selective VEGF-A blockade in mice. Blood (2006) 107(2):550-557.
   PubMed Web of Science ®Google Scholar
• LIANG WC, WU X, PEALE FV et al.: Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF. J. Biol. Chem. (2006) 281(2):951-961.
   PubMed Web of Science ®Google Scholar
• HWANG WY, FOOTE J: Immunogenicity of engineered antibodies. Methods (2005) 36(1):3-10.
   PubMed Web of Science ®Google Scholar
• ANDERSON PJ: Tumor necrosis factor inhibitors: clinical implications of their different immunogenicity profiles. Semin. Arthritis Rheum. (2005) 34(5 Suppl.1):19-22.
   PubMed Web of Science ®Google Scholar
• WEINBLATT ME, KEYSTONE EC, FURST DE et al.: Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. (2003) 48(1):35-45.
   PubMed Web of Science ®Google Scholar
• HERZYK DJ: The immunogenicity of therapeutic cytokines. Curr. Opin. Mol. Ther. (2003) 5(2):167-171.
   Web of Science ®Google Scholar
• HARRIS LJ, LARSON SB, HASEL KW, MCPHERSON A: Refined structure of an intact IgG2a monoclonal antibody. Biochemistry (1997) 36(7):1581-1597.
   PubMed Web of Science ®Google Scholar
• CHOTHIA C, LESK AM: Canonical structures for the hypervariable regions of immunoglobulins. J. Mol. Biol. (1987) 196:901-917.
   PubMed Web of Science ®Google Scholar
• GORDON NC, PAN B, HYMOWITZ SG et al.: BAFF/BLyS receptor 3 comprises a minimal TNF receptor-like module that encodes a highly focused ligand-binding site. Biochemistry (2003) 42(20):5977-5983.
   PubMed Web of Science ®Google Scholar
• VAJDOS FF, ADAMS CW, BREECE TN et al.: Comprehensive functional maps of the antigen-binding site of an anti-ErbB2 antibody obtained with shotgun scanning mutagenesis. J. Mol. Biol. (2002) 320(2):415-428.
   PubMed Web of Science ®Google Scholar